- PROFESSOR Psychiatry
Psychiatry, American Board of Psychiatry and Neurology
MD, Harvard Medical School
Wilmer Eye Institute at Johns Hopkins
Bronx Municipal Hospital Center
National Institute of Mental Health
Albert Einstein College of Medicine
- Dr. Rieder's interests have been in the areas of schizophrenia and genetics.
As of 1979, Dr. Rieder became a residency education director, and has focused his academic work and publications on teaching and education. He developed both clinical and research training programs, first at Columbia University and beginning in 2007, at Mount Sinai.
For these efforts, Dr. Rieder received the highest award for psychiatric education, the American Psychiatric Association and National Institute of Mental Health’s Vesterrmark Award, in 2008.
Posner J, Stewart J, Rieder RO. Neurobiological formulations: integrating clinical and biological psychiatry. Academic Psychiatry 2007; 31: 479-484.
Mullen L, Rieder RO, Glick R, Luber B, Rosen PJ. Testing psychodynamic psychotherapy skills among psychiatric residents: The psychodynamic psychotherapy competency test. American Journal of Psychiatry 2004; 161: 1658-1664.
Gershon ES, Rieder RO. Major disorders of mind and brain. Scientific American 1992; 267: 126-133.
Rieder RO, Donnelly EF, Herdt JR, Waldman I. Sulcal prominence in young chronic schizophrenic patients: CT scan findings associated with impairment on neuropsychological tests. Psychiatry Research 1979; 1: 1-23.
Buchsbaum MS, Rieder RO. Biologic heterogeneity and psychiatric research: Platelet MAO as a case study. Archives of General Psychiatry 1979; 36: 1163-1172.
Rieder RO, Gershon E, . Genetic strategies in biological psychiatry. Archives of General Psychiatry 1978; 35: 866-873.
Rieder RO, Rosenthal D, Wender PH, Blumenthal H. The offspring of schizophrenics: Fetal and neonatal deaths. Archives of General Psychiatry 1975; 32: 200-211.
Rieder RO. Teaching about schizophrenia. Schizophrenia Bulletin 1974; 11: 9-15.
Rieder RO. The origins of our confusion about schizophrenia. Psychiatry 1974; 37: 197-208.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Rieder did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.